XERIS BIOPHARMA HOLDINGS, INC. (XERS) Operating margin 2020–2025
XERIS BIOPHARMA HOLDINGS, INC. (XERS) operating margin by fiscal year — reported operating income divided by reported revenue.
8.5%FY2025 · since FY2020: -414.5% → 8.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 8.5% | +25.1 pp |
| FY2024 | -16.6% | +10.3 pp |
| FY2023 | -26.8% | +47.5 pp |
| FY2022 | -74.3% | +157.9 pp |
| FY2021 | -232.2% | +182.3 pp |
| FY2020 | -414.5% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More XERS financial trends
XERS RevenueXERS Net incomeXERS Net marginXERS Gross profitXERS Gross marginXERS Operating incomeXERS Operating cash flowXERS Free cash flowXERS Capital expendituresXERS Return on equityXERS Stock buybacksXERS Dividends paidXERS Total assetsXERS Total liabilitiesXERS Shareholders’ equityXERS overview →